Clinical Trial Will Assess IVIG for Treating COVID-19
Octapharma USA is supporting a new investigator-initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, Calif., focused on treating the most critical coronavirus patients who are experiencing respiratory failure who become ventilator dependent.
Novartis Initiates Phase III Trial of Ilaris to Treat COVID-19 Patients with Pneumonia
Novartis has initiated a Phase III clinical trial to examine the efficacy of utilizing canakinumab (Ilaris), an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.
Central Repository Created for SARS-CoV 2 Clinical Trials
Inato, a marketplace that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, has unveiled its anticovid platform, a comprehensive, central repository for all existing clinical trials for SARS-CoV 2 (the virus that causes COVID-19).
FcRn Antagonist Boosts Platelet Counts, Reduces Bleeding Risk in Patients with Immune Thrombocytopenic Purpura
Efgartigimod, an investigational human IgG1 Fc fragment, induced a rapid reduction in total IgG levels and clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according to findings from a Phase II, placebo-controlled multinational study.
High-Titer Inhibitors Reduced in PUPs with Severe Hemophilia A Treated with Fourth Generation Recombinant Factor VIII
A study in previously untreated patients (PUPs) with severe hemophilia A found replacement therapy with a fourth-generation recombinant factor VIII (FVIII) product was associated with an incidence of high-titer inhibitors similar to the rate seen in a landmark trial evaluating plasma-derived FVIII products.
Trivalent HBV Vaccine Superior in Efficacy in Adults 45 Years and Older
A Phase III study has found a trivalent hepatitis B virus (HBV) vaccine demonstrated superiority in adults 45 years and older and noninferior in adults older than 18 years compared with a monovalent vaccine.
Plasma-Derived ApoA-1
Findings suggest CSL112 can boost cholesterol efflux capacity in patients with impaired endogenous HDL function. Encouragingly, several studies have documented its ability to reduce atherosclerotic plaque volume.
NIH to Evaluate Experimental Adjuvants for Seasonal Influenza Vaccine
The National Institutes of Health (NIH) is conducting an early-stage clinical trial to evaluate the safety and efficacy of two licensed seasonal influenza vaccines administered with or without novel adjuvants.
Anti-Influenza Hyperimmune Immune Globulin Not Effective in Hospitalized Adults with Influenza Infection
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.